Bristol-Myers Squibb announced that it will stop manufacturing the antibiotic Tequin. However, the drug is not being pulled from pharmacy shelves right now. The rights to the drug will be returned to a Japanese company, Kyorin Pharmaceutical. A recently published study found that elderly patients using Tequin, were at an increased risk of developing hypoglycemia and hyperglycemia. Those findings prompted an FDA alert and stronger warning labels for the drug. Also, Public Citizen Health Research Group has petitioned the FDA to ban Tequin, saying that it has been linked to at least 20 deaths and nearly 200 hospitalizations.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.